Swiss Nordic Bio 2026: Sprint Bioscience harnesses fragment based drug design to discover small molecules that it licenses out to partners - it recently scored a deal with Gilead
CEO Johan Emilsson describes the approach and business model. Much of the work is done in oncology.
Coverage brought to you by










.png)